In patients with NSCLC, premenopausal females experienced a higher incidence of irAEs during anti-programmed cell death protein 1 (PD-1) therapy (67%) compared with postmenopausal females (60%) and males (40%) [56]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.